Cargando…

Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)

Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and...

Descripción completa

Detalles Bibliográficos
Autores principales: Khongthaw, Banlambhabok, Dulta, Kanika, Chauhan, Pankaj Kumar, Kumar, Vinod, Ighalo, Joshua O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436159/
https://www.ncbi.nlm.nih.gov/pubmed/36050507
http://dx.doi.org/10.1007/s10787-022-01061-4
_version_ 1784781301617786880
author Khongthaw, Banlambhabok
Dulta, Kanika
Chauhan, Pankaj Kumar
Kumar, Vinod
Ighalo, Joshua O.
author_facet Khongthaw, Banlambhabok
Dulta, Kanika
Chauhan, Pankaj Kumar
Kumar, Vinod
Ighalo, Joshua O.
author_sort Khongthaw, Banlambhabok
collection PubMed
description Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and pharmacological benefits. COVID-19 (coronavirus disease 19) is an infectious disease caused by the SARS-CoV-2 virus, which has recently emerged as one of the world's leading causes of death. Patients may be asymptomatic or show signs of respiratory, cytokine release syndrome, gastrointestinal, or even multiple organ failure, all of which can lead to death. In COVID-19, inflammation, and cytokine storm are the key pathogenic mechanisms, according to SARS-CoV-2 infection symptoms. ARDS develops in some vulnerable hosts, which is accompanied by an inflammatory "cytokine syndrome" that causes lung damage. Immunological and inflammatory markers were linked to disease severity in mild and severe COVID-19 cases, implying that inflammatory markers, including IL-6, CRP, ESR, and PCT were significantly linked with COVID-19 severity. Patients with severe illness have reduced levels of several immune subsets, including CD4 + T, NK, and CD8 + cells. As a result, lycopene can be commended for bolstering physiological defenses against COVID-19 infections
format Online
Article
Text
id pubmed-9436159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-94361592022-09-02 Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) Khongthaw, Banlambhabok Dulta, Kanika Chauhan, Pankaj Kumar Kumar, Vinod Ighalo, Joshua O. Inflammopharmacology Review Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and pharmacological benefits. COVID-19 (coronavirus disease 19) is an infectious disease caused by the SARS-CoV-2 virus, which has recently emerged as one of the world's leading causes of death. Patients may be asymptomatic or show signs of respiratory, cytokine release syndrome, gastrointestinal, or even multiple organ failure, all of which can lead to death. In COVID-19, inflammation, and cytokine storm are the key pathogenic mechanisms, according to SARS-CoV-2 infection symptoms. ARDS develops in some vulnerable hosts, which is accompanied by an inflammatory "cytokine syndrome" that causes lung damage. Immunological and inflammatory markers were linked to disease severity in mild and severe COVID-19 cases, implying that inflammatory markers, including IL-6, CRP, ESR, and PCT were significantly linked with COVID-19 severity. Patients with severe illness have reduced levels of several immune subsets, including CD4 + T, NK, and CD8 + cells. As a result, lycopene can be commended for bolstering physiological defenses against COVID-19 infections Springer International Publishing 2022-09-01 2022 /pmc/articles/PMC9436159/ /pubmed/36050507 http://dx.doi.org/10.1007/s10787-022-01061-4 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Khongthaw, Banlambhabok
Dulta, Kanika
Chauhan, Pankaj Kumar
Kumar, Vinod
Ighalo, Joshua O.
Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title_full Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title_fullStr Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title_full_unstemmed Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title_short Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
title_sort lycopene: a therapeutic strategy against coronavirus disease 19 (covid- 19)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436159/
https://www.ncbi.nlm.nih.gov/pubmed/36050507
http://dx.doi.org/10.1007/s10787-022-01061-4
work_keys_str_mv AT khongthawbanlambhabok lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19
AT dultakanika lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19
AT chauhanpankajkumar lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19
AT kumarvinod lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19
AT ighalojoshuao lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19